ID
14490
Beschrijving
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00639691
Link
https://clinicaltrials.gov/show/NCT00639691
Trefwoorden
Versies (1)
- 18-04-16 18-04-16 -
Houder van rechten
CC BY-NC 3.0
Geüploaded op
18 april 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Asthma NCT00639691
Eligibility Asthma NCT00639691
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
comorbidity
Datatype
boolean
Alias
- UMLS CUI [1]
- C0009488
Beschrijving
pregnancy or lactation
Datatype
boolean
Alias
- UMLS CUI [1]
- C0032961
- UMLS CUI [2]
- C0006147
Beschrijving
lung disease
Datatype
boolean
Alias
- UMLS CUI [1]
- C0024115
Beschrijving
anaphylactoid or anaphylactic reaction
Datatype
boolean
Alias
- UMLS CUI [1]
- C0340865
- UMLS CUI [2]
- C0002792
Beschrijving
warfarin immunomodulatory therapy or antiplatelet therapy
Datatype
boolean
Alias
- UMLS CUI [1]
- C0043031
- UMLS CUI [2]
- C1963758
- UMLS CUI [3]
- C1096021
Similar models
Eligibility Asthma NCT00639691
- StudyEvent: Eligibility
C0040223 (UMLS CUI [1,2])
C0155877 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
C0002792 (UMLS CUI [2])
C1963758 (UMLS CUI [2])
C1096021 (UMLS CUI [3])
Geen commentaren